Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. Issue 10085 (3rd June 2017)

• Record Type: Journal Article
• Authors: Viner, Russell; White, Billy; Christie, Deborah
• Is Part Of: Lancet. Volume 389:Issue 10085(2017)
• Page Start: 2252
• Page End: 2260
• Publication Date: 2017-06-03
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Medicine; Electronic journals; Periodicals; 610.5
• DOI: 10.1016/S0140-6736(17)31371-5
• Languages: English
• ISSNs: 0140-6736

Abstract

Summary: Type 2 diabetes in adolescence manifests as a severe progressive form of diabetes that frequently presents with complications, responds poorly to treatment, and results in rapid progression of microvascular and macrovascular complications. Although overall still a rare disease, adolescent type 2 diabetes now poses major challenges to paediatric and adult diabetes services in many countries. Therapeutic options are heavily curtailed by a dearth of knowledge about the condition, with low numbers of participants and poor trial recruitment impeding research. Together with lifestyle modification, metformin remains the first-line therapy for adolescents with type 2 diabetes, although the majority rapidly progress to treatment failure and insulin therapy. Early bariatric surgery is controversial but has great potential to transform outcomes. Health systems must respond by both concentrating patients in specialist clinical services integrated with translational research programmes, but also by joining up with local health and social care services to improve engagement and uptake of services.